Immunocore (IMCR) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Immunocore (IMCR) over the past year, gaining 16.7% versus a loss of 14.1%. Immunocore is the larger company by market cap ($1.49 billion vs $1.43 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | RAPP |
|---|---|---|
| Share price | $28.93 | $29.83 |
| Market cap | $1.49B | $1.43B |
| 1-day change | -1.63% | -3.35% |
| YTD return | -15.27% | +1.71% |
| 1-year return | -14.06% | +16.72% |
| 5-year return | -22.61% | — |
| EPS (TTM) | $-0.36 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $52.93 |
| 52-week low | $27.56 | $23.75 |
| Distance from 52-week high | -28.95% | -43.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.83% | +111.37% |
| Average volume | 447.09K | 359.60K |
| Shares outstanding | 51.50M | 47.98M |
| Employees | 524 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RAPP has outperformed IMCR by 30.8 percentage points over the past year.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
IMCR vs RAPP FAQ
Which is bigger, Immunocore or Rapport Therapeutics?
Immunocore (IMCR) is larger, with a market capitalization of $1.49B compared with $1.43B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, IMCR or RAPP?
RAPP returned +16.72% over the past 12 months, compared with -14.06% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Rapport Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for Rapport Therapeutics.